Trial Profile

A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sorafenib (Primary)
Indications Thyroid cancer
Focus Registrational; Therapeutic Use
Acronyms DECISION
Sponsors Bayer; Bayer HealthCare; Bayer Yakuhin; Onyx Pharmaceuticals

Most Recent Events

26 Sep 2019 Results of a retrospective, exploratory biomarker analysis assessing prognostic biomarkers for disease outcome and predictive biomarkers for sorafenib treatment, published in the Clinical Cancer Research
02 Dec 2017 This trial was completed in Sweden (end date: 30/08/2017), according to European Clinical Trials Database.
02 Dec 2017 This trial was completed in Netherlands, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com